Roles of cardiovascular risk factors in endothelial nitric oxide synthase regulation: An update

Current Pharmaceutical Design

Volumn 20, Issue 22, 2014, Pages 3563-3578

  Jamaluddin, Md Saha ^a   Liang, Zhengdong ^a   Lü, Jian Ming ^a   Yao, Qizhi ^a   Chen, Changyi ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Cardiovascular risk factor; Endothelial dysfunction; eNOS; Nitric oxide

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; ANTIRETROVIRUS AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; SERUM AMYLOID A; URIC ACID; NITRIC OXIDE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHLAMYDIAL PNEUMONIA; DIABETES MELLITUS; ENZYME REGULATION; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SMOKING; ENDOTHELIUM CELL; ENZYMOLOGY; METABOLISM; RISK FACTOR;

CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RISK FACTORS;

EID: 84907204654     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660744     Document Type: Article

References (335)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.
2. Grundy SM, Pasternak R, Greenland P, Smith Jr S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999; 34: 1348-59.
3. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56: e50-103.
4. Franchini M, Mannucci PM. Air pollution and cardiovascular disease. Thromb Res 2012; 129: 230-4.
5. Dubé MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008; 118: e36-40.
6. Lipshultz SE, Mas CM, Henkel JM, Franco VI, Fisher SD, Miller TL. HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults. Expert Rev Anti Infect Ther 2012; 10: 661-74.
7. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: Additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-8.
8. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: From Marvel to Menace. Circulation 2006; 113: 1708-14.
9. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
10. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res 1983;53(5): 557-73.
11. Cherry PD, Furchgott RF, Zawadzki JV, Jothianandan D. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA 1982; 79: 2106-10.
12. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3': 5'-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203-7.
13. Murad F, Arnold WP, Mittal CK, Braughler JM. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Adv Cyclic Nucleotide Res 1979; 11: 175-204.
14. Rapoport RM, Murad F. Agonist-induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cGMP. Circ Res 1983;52(3): 352-7.
15. Gruetter CA, Barry BK, McNamara DB, Gruetter DY, Kadowitz PJ, Ignarro L. Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase by nitric oxide, nitroprusside and a carcinogenic nitrosoamine. J Cyclic Nucleotide Res 1979; 5: 211-24.
16. Ignarro LJ, Adams JB, Horwitz PM, Wood KS. Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms. J Biol Chem 1986; 261: 4997-5002.
17. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium- derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9.
18. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-6.
19. Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Bloch KD. Cloning and expression of a cDNA encoding human endotheliumderived relaxing factor/nitric oxide synthase. J Biol Chem 1992; 267: 14519-522.
20. Marsden PA, Schappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, Lamas S, Michel T. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett 1992; 307: 287-93.
21. Marsden PA, Heng HHQ, Scherer SW, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993; 268: 17478-88.
22. Robinson LJ, Weremowicz S, Morton CC, Michel T. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics 1994; 19: 350-7.
23. Schulz E, Jansen T, Wenzel P, Daiber A, Münzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008; 10: 1115-26.
24. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2008; 40: 180-96.
25. Huang PL. ENOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab 2009; 20: 295-302.
26. Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens Res 2011; 34: 665-73.
27. Searles CD. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. J Physiol Cell Physiol 2006; 291: C803-16.
28. Zhang MX, Ou H, Shen YH, Wang J, Coselli J, and Wang XL. Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci USA 2005; 102: 16967-72.
29. Li M, Marin-Muller C, Bharadwaj U, Chow KH, Yao Q, Chen C. MicroRNAs: control and loss of control in human physiology and disease. World J Surg 2009; 33: 667-84.
30. Dedio J, Koenig P, Wohlfart P, Schroeder C, Kummer W, Mueller-Esterl W. NOSIP, a novel modulator of endothelial nitric oxide synthase activity. FASEB J 2001; 15: 79-89.
31. Zimmermann K, Opitz N, Dedio J, Renne C, Mueller-Esterl W, Oess S. NOSTRIN: a protein modulating nitric oxide release and subcellular distribution of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2002; 99: 17167-72.
32. Icking A, Matt S, Opitz N, Wiesenthal A, Mueller-Esterl W, Schilling K. NOSTRIN functions as a homotrimeric adaptor protein facilitating internalization of eNOS. J Cell Sci 2005; 118: 5059-69.
33. Chen ZP, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999; 443: 285-9.
34. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Aktdependent phosphorylation. Nature 1999; 399: 601-5.
35. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endotheliumderived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
36. Harris MB, Ju H, Venema VJ, et al. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem 2001; 276: 16587-91.
37. Thomas SR, Chen K, Keaney JF. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinasedependent signaling pathway. J Biol Chem 2002; 277: 6017-24.
38. Lin MI, Fulton D, Babbitt R, et al. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of l-arginine metabolism to efficient nitric oxide production. J Biol Chem 2003;278: 44719-26.
39. Lenasi H, Kohlstedt K, Fichtlscherer B, Mülsch A, Busse R, Fleming I. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495 Cardiovasc Res 2003;59: 844-53.
40. Loot AE, Schreiber JG, Fisslthaler B, Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med. 2009; 206: 2889-96.
41. Chen CA, Wang TY, Varadharaj S, et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010; 468: 1115-8.
42. Cho DH, Seo J, Park JH, et al. Cyclin-dependent kinase 5 phosphorylates endothelial nitric oxide synthase at serine 116. Hypertension 2010;55(2): 345-52.
43. Lee CH, Wei YW, Huang YT, et al. CDK5 phosphorylates eNOS at Ser-113 and regulates NO production. J Cell Biochem 2010; 110: 112-7.
44. Closs EI, Ostad MA, Simon A, et al. Impairment of the extrusion transporter for asymmetric dimethyl-L-arginine: a novel mechanism underlying vasospastic angina. Biochem Biophys Res Commun 2012; 423: 218-23.
45. Toda N, Ayajiki K, Okamura T. Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol Rev 2007; 59: 54-87.
46. Powers SK, Jackson MJ. Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev 2008; 88: 1243-76.
47. Zhang Z, Wang M, Xue SJ, Liu DH, Tang YB. Simvastatin ameliorates angiotensin II-induced endothelial dysfunction through restoration of Rho-BH4-eNOS-NO pathway. Cardiovasc Drugs Ther 2012; 26: 31-40.
48. Shatanawi A, Romero MJ, Iddings JA, et al. Angiotensin IIinduced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 2011; 300: C1181-92.
49. Lobysheva I, Rath G, Sekkali B, et al. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol 2011; 31: 2098-105.
50. Cai H, Li Z, Dikalov S, et al. NAD [P]H oxidase-derived hydrogen peroxide mediates endothelial nitric oxide production in response to angiotensin II. J Biol Chem 2002; 277: 48311-7.
51. Presta I, Tassone EJ, Andreozzi F, et al. Angiotensin II type 1 receptor, but no type 2 receptor, interferes with the insulin-induced nitric oxide production in HUVECs. Atherosclerosis 2011; 219: 463-7.
52. Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR. Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab 2012; 302: E201-8.
53. Kishi T, Hirooka Y, Konno S, Sunagawa K. Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. J Hypertens 2012; 30: 1646-55.
54. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204: 2449-60.
55. Wenzel P, Knorr M, Kossmann S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation 2011; 124: 1370-81.
56. Rodella LF, Favero G, Rossini C, Foglio E, Reiter RJ, Rezzani R. Endothelin-1 as a potential marker of melatonin's therapeutic effects in smoking-induced vasculopathy. Life Sci 2010;87(17-18): 558-64.
57. Wagner L, Laczy B, Tamaskó M, et al. Cigarette smoke-induced alterations in endothelial nitric oxide synthase phosphorylation: role of protein kinase C. Endothelium 2007; 14: 245-55.
58. Michaud SE, Dussault S, Groleau J, Haddad P, Rivard A. Cigarette smoke exposure impairs VEGF-induced endothelial cell migration: role of NO and reactive oxygen species. J Mol Cell Cardiol 2006; 41: 275-84.
59. Edirisinghe I, Yang SR, Yao H, et al. VEGFR-2 inhibition augments cigarette smoke-induced oxidative stress and inflammatory responses leading to endothelial dysfunction. FASEB J 2008;22(7): 2297-310.
60. Jin ZG. Ueba H. Tanimoto T. Lungu AO. Frame MD. Berk BC. Ligand-independent activation of vascular endothelial growth fac tor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 2003; 93: 354-63.
61. Arunachalam G, Yao H, Sundar IK, Caito S, Rahman I: SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem Biophys Res Commun 2010; 393: 66-72.
62. Steffen Y, Vuillaume G, Stolle K, et al. Cigarette smoke and LDL cooperate in reducing nitric oxide bioavailability in endothelial cells via effects on both eNOS and NADPH oxidase. Nitric Oxide 2012; 27: 176-84
63. Ferrer E, Peinado VI, Díez M, et al. Effects of cigarette smoke on endothelial function of pulmonary arteries in the guinea pig. Respir Res 2009; 10: 76.
64. Su Y, Han W, Giraldo C, De Li Y, Block ER. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1998; 19: 819-25.
65. Cui Z, Han Z, Li Z, et al. Involvement of calpain-calpastatin in cigarette smoke-induced inhibition of lung endothelial nitric oxide synthase. Am J Respir Cell Mol Biol 2005; 33: 513-20.
66. Juonala M, Magnussen CG, Venn A, et al. Parental smoking in childhood and brachial artery flow-mediated dilatation in young adults: the Cardiovascular Risk in Young Finns study and the Childhood Determinants of Adult Health study. Arterioscler Thromb Vasc Biol 2012; 32: 1024-31.
67. Li D, Mehta JL. Oxidized LDL, a critical factor in atherogenesis. Cardiovas Res 2005; 68: 353-4.
68. Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000; 28: 12633-8.
69. Thum T, Fraccarollo D, Schultheiss M, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 2007; 56: 666-74.
70. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest 2002; 109: 817-26.
71. Lubos E, Handy DE, Loscalzo J. Role of oxidative stress and nitric oxide in atherothrombosis. Front Biosci 2008; 13: 5323-44.
72. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoproteininduced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000;275: 11278-83.
73. Ryoo S, Bhunia A, Chang F, Shoukas A, Berkowitz DE, Romer. OxLDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signaling. Atherosclerosis 2011; 214: 279-87.
74. Peng ZY, Zhao SP, He BM, Peng DQ, Hu M. Protective effect of HDL on endothelial NO production: the role of DDAH/ADMA pathway. Mol Cell Biochem 2011; 351: 243-9.
75. Böger RH, Bode-Böger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-74.
76. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493.e1-8.
77. Eid HM, Eritsland J, Larsen J, et al. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003; 166: 279-84.
78. Yoo JH, Lee SC. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425-30.
79. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the Athero Gene Study. Circ Res 2005; 97: e53-9.
80. Toma L, Stancu CS, Sanda GM, Sima AV. Anti-oxidant and antiinflammatory mechanisms of amlodipine action to improve endothelial cell dysfunction induced by irreversibly glycated LDL. Biochem Biophys Res Commun 2011; 411: 202-7.
81. Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem Biophys Res Commun 2009; 390: 877-82.
82. Dong Y, Wu Y, Wu M, et al. Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase. J Cell Mol Med 2009; 13: 2899-910.
83. Parthasarathy S, Barnett J. Phospholipase A2 activity of low density lipoprotein: evidence for an intrinsic phospholipase A2 activity of apoprotein B100. Proc Natl Acad Sci USA 1990; 87: 9741-5.
84. Stiko A, Regnström J, Shah PK, Cercek B, Nilsson J. Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol 1996; 16: 194-200.
85. Yokoyama M, Hirata K, Miyake R, Akita H, Ishikawa Y, Fukuzaki H. Lysophosphatidylcholine: essential role in the inhibition of endothelium- dependent vasorelaxation by oxidized low density lipoprotein. Biochem Biophys Res Commun 1990; 168: 301-8.
86. Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J Biol Chem. 1995; 270: 319-24.
87. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-2.
88. Choi S, Park S, Liang GH, Kim JA, Suh SH. Superoxide generated by lysophosphatidylcholine induces endothelial nitric oxide synthase downregulation in human endothelial cells. Cell Physiol Biochem 2010;25(2-3): 233-40.
89. Millanvoye-Van Brussel E, Topal G, Brunet A, et al. Lysophosphatidylcholine and 7-oxocholesterol modulate Ca2+ signals and inhibit the phosphorylation of endothelial NO synthase and cytosolic phospholipase A2. Biochem J 2004; 380: 533-9.
90. Safaya R, Chai H, Kougias P, et al. Effect of lysophosphatidylcholine on vasomotor functions of porcine coronary arteries. J Surg Res 2005; 126: 182-8.
91. Feng M, Liu L, Guo Z, Xiong Y. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine. Eur J Pharmacol 2008; 584: 49-56.
92. Noguchi K, Herr D, Mutoh T, Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009; 9: 15-23.
93. Yanagida K, Kurikawa Y, Shimizu T, Ishii S. Current progress in non-Edg family LPA receptor research. Biochim Biophys Acta 2013; 1831: 33-41.
94. Kou R, Igarashi J, Michel T. Lysophosphatidic acid and receptormediated activation of endothelial nitric-oxide synthase. Biochemistry 2002; 41: 4982-8.
95. Chen C, Ochoa LN, Kagan A, et al. Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Atherosclerosis 2012; 222: 74-83.
96. Wei X, Schneider JG, Shenouda SM, et al. De novo lipogenesis maintains vascular homeostasis through endothelial nitric-oxide synthase [eNOS] palmitoylation. J Biol Chem 2011; 286: 2933-45.
97. Cao C, Zhang H, Gong L, He Y, Zhang N. High glucose conditions suppress the function of bone marrow-derived endothelial progenitor cells via inhibition of the eNOS-caveolin-1 complex. Mol Med Report 2012; 5: 341-6.
98. Taguchi K, Kobayashi T, Takenouchi Y, Matsumoto T, Kamata K. Angiotensin II causes endothelial dysfunction via the GRK2/Akt/eNOS pathway in aortas from a murine type 2 diabetic model. Pharmacol Res 2011; 64: 535-46.
99. Taguchi K, Kobayashi T, Matsumoto T, Kamata K. Dysfunction of endothelium-dependent relaxation to insulin via PKC-mediated GRK2/Akt activation in aortas of ob/ob mice. Am J Physiol Heart Circ Physiol 2011; 301: H571-83.
100. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. Inhibitor of G protein-coupled receptor kinase 2 normalizes vascular endothelial function in type 2 diabetic mice by improving β -arrestin 2 translocation and ameliorating Akt/eNOS signal dysfunction. Endocrinology 2012; 153: 2985-96.
101. Taguchi K, Matsumoto T, Kamata K, Kobayashi T. G Proteincoupled receptor kinase 2, with β-Arrestin 2, impairs insulininduced Akt/endothelial nitric oxide synthase signaling in ob/ob mouse aorta. Diabetes 2012; 61: 1978-85.
102. Youn JY, Gao L, Cai H. The p47(phox)- and NADPH oxidase organiser 1 (NOXO1)-dependent activation of NADPH oxidase 1 (NOX1) mediates endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction in a streptozotocin-induced murine model of diabetes. Diabetologia 2012; 55: 2069-79.
103. Schuhmacher S, Oelze M, Bollmann F, et al. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. Diabetes 2011; 60: 2608-16.
104. Chun L, Junlin Z, Aimin W, Niansheng L, Benmei C, Minxiang L. Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 2011; 93: 77-85.
105. Zhang QJ, Holland WL, Wilson L, et al. Ceramide mediates vascular dysfunction in diet-induced obesity by PP2A-mediated dephosphorylation of the eNOS-Akt complex. Diabetes 2012; 61: 1848-59.
106. Bismuth J, Chai H, Lin PH, Yao Q, Chen C. Lactosylceramide causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Med Sci Monit 2009; 15: BR270-4.
107. Gladwin MT. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. J Clin Invest 2006; 116: 2330-2.
108. Witte K, Jacke K, Stahrenberg R, et al. Dysfunction of soluble guanylyl cyclase in aorta and kidney of Goto-Kakizaki rats: influence of age and diabetic state. Nitric Oxide 2002; 6: 85-95.
109. Liu S, Ma X, Gong M, Shi L, Lincoln T, Wang S. Glucose downregulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic Biol Med 2007; 42: 852-63.
110. Altinova AE, Arslan M, Sepici-Dincel A, et al. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007; 92: 1881-5.
111. Sugai M, Ohta A, Ogata Y, et al. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J 2007; 54: 303-9.
112. Stirban A, Negrean M, Stratmann B, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-71.
113. Tan KC, Chow WS, Ai VH, Metz C, Bucala R, Lam KS. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 2002; 25: 1055-9.
114. Soro-Paavonen A, Zhang WZ, Venardos K, et al. Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J Hypertens 2010; 28: 780-8.
115. Rojas A, Romay S, Gonzalez D, Herrera B, Delgado R, Otero K. Regulation of endothelial nitric oxide synthase expression by albumin- derived advanced glycosylation end products. Circ Res 2000; 86: E50-4.
116. Xu B, Chibber R, Ruggerio D, Kohner E, Ritter J, Ferro A. Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J 2003; 17: 1289-91.
117. Chakravarthy U, Hayes RG, Stitt AW, McAuley E, Archer DB. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998; 47: 945-52.
118. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87: 432-8.
119. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest 1992; 90: 1110-15.
120. Yan SD, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 1994; 269: 9889-97.
121. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90.
122. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt AM, Wautier JL. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-94.
123. Su J, Lucchesi PA, Gonzalez-Villalobos RA, et al. Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2008; 28: 1432-8.
124. Zhuang X, Pang X, Zhang W, Wu W, Zhao J, Yang H, Qu W. Effects of zinc and manganese on advanced glycation end products (AGEs) formation and AGEs-mediated endothelial cell dysfunction. Life Sci 2012; 90: 131-9.
125. Hussain S, Ali SF. Manganese scavenges superoxide and hydroxyl radicals: an in vitro study in rats. Neurosci Lett 1999; 261: 21-4.
126. Tomat AL, Costa MA, Girgulsky LC, et al. Zinc deficiency during growth: influence on renal function and morphology. Life Sci 2007; 80: 1292-302.
127. Del Turco S, Navarra T, Gastaldelli A, Basta G. Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvasc Res 2011; 82: 73-6.
128. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
129. Chen C, Jiang J, Lü JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2010; 299: H193-201.
130. Ou HC, Lee WJ, Wu CM, Chen JF, Sheu WH. Aspirin prevents resistin-induced endothelial dysfunction by modulating AMPK, ROS, and Akt/eNOS signaling. J Vasc Surg 2012; 55: 1104-15.
131. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J Vasc Surg 2005; 41: 691-8.
132. Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol 2011; 51: 144-55.
133. Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: A Multifaceted Molecule with Diverse Roles in Physiology and Pathophysiology. Annu Rev Nutr 2012; 32: 229-43.
134. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-80.
135. Kadoglou NP, Sailer N, Moumtzouoglou A, et al. Visfatin [nampt] and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2010; 118: 75-80.
136. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol 2008;69: 878-84.
137. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes [ACS] in humans. Clin Endocrinol 2009; 71: 202-7.
138. Lu LF, Yang SS, Wang CP, et al. Elevated visfatin/pre-B-cell colonyenhancing factor plasma concentration in ischemic stroke. J. Stroke Cerebrovasc Dis 2009; 18: 354-9.
139. Gunes F, Akbal E, Cakir E, Akyurek O, Altunbas M, Ozbek M. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51: 553-7.
140. Adya R, Tan BK, Chen J, Randeva HS. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care 2008;31: 758-60.
141. Adya R, Tan BK, Chen J, Randeva HS. Pre-B cell colony enhancing factor (PBEF)/visfatin induces secretion of MCP-1 in human endothelial cells: role in visfatin-induced angiogenesis. Atherosclerosis 2009; 205: 113-9.
142. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production viaMAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-65.
143. Lee WJ, Wu CS, Lin H, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NFkappaB pathway. Int J Obes 2009; 33: 465-72.
144. Kim SR, Bae YH, Bae SK, et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886-95.
145. Bae YH, Park HJ, Kim SR, et al. Notch1 mediates visfatin-induced FGF-2 up-regulation and endothelial angiogenesis. Cardiovasc Res 2011; 89: 436-45.
146. Park JW, Kim WH, Shin SH, et al. Visfatin exerts angiogenic effects on human umbilical vein endothelial cells through the mTOR signaling pathway. Biochim Biophys Acta 2011; 1813: 763-71.
147. Cirillo P, Di Palma V, Maresca F, et al. The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle. Thromb Res 2012; 130: 403-8.
148. Kim JY, Bae YH, Bae MK, et al. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim Biophys Acta 2009; 1793: 1759-67.
149. Kim SR, Jung YH, Park HJ, et al. Upregulation of thromboxane synthase mediates visfatin-induced interleukin-8 expression and angiogenic activity in endothelial cells. Biochem Biophys Res Commun 2012; 418: 662-8.
150. Ye SQ, Zhang LQ, Adyshev D, et al. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation. Microvasc Res 2005; 70: 142-51.
151. Yilmaz MI, Saglam M, Carrero JJ, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-65.
152. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 451-8.
153. Reimann M, Ziemssen T, Huisman HW, et al. Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function. Obesity 2009; 17: 2210-5.
154. Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage? Clin Transplant 2009; 23: 241-8.
155. Bessa SS, Hamdy SM, El-Sheikh RG. Serum visfatin as a nontraditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian study. Eur J Intern Med 2010; 21: 530-5.
156. Malyszko J, Malyszko JS, Mysliwiec M. Visfatin and endothelial function in dialyzed patients. Nephrology 2010; 15: 190-6.
157. Mu J, Feng B, Ye Z, et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol 2011; 24: 177-84.
158. Pepene CE. Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol 2012; 76: 119-25.
159. Xia M, Zhang C, Boini KM, Thacker AM, Li PL. Membrane raftlysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin. Cardiovasc Res 2011; 89: 401-9.
160. Vallejo S, Romacho T, Angulo J, et al. Visfatin impairs endothelium- dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One 2011; 6(11): e27299.
161. Boini KM, Zhang C, Xia M, et al. Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells. Biochim Biophys Acta 2010; 1801: 1294-304.
162. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun 2009; 383: 503-8.
163. Lovren F, Pan Y, Shukla PC, et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009; 296: E1440-9.
164. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in Adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-9.
165. Hadigan C, Meigs JB, Wilson PW, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36: 909-16.
166. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIV infected patients: comparison with observed events in the D: A: D Study. HIV Med 2006; 7: 218-30.
167. Knobel H, Jerico C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS 2007; 21: 452-7.
168. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
169. Moreira Guimaraes MM, Bartolomeu Greco D, Ingles Garces AH, et al. Coronary heart disease risk assessment in HIV-infected patients: a comparison of Framingham, PROCAM and SCORE risk assessment functions. Int J Clin Pract 2010; 64: 739-45.
170. Barros ZM, de Alencar Ximenes RA, Miranda-Filho DB, et al. Comparison between the Framingham and prospective cardiovacular of Munster scores for risk assessment of coronary heart disease in human immunodeficiency virus-positive patients in Pernambuco, Brazil. Metab Syndr Relat Disord 2010; 8: 489-97.
171. Edwards-Jackson N, Kerr S, Tieu H, et al. Cardiovascular risk assessment in persons with HIV infection in the developing world: comparing three risk equations in a cohort of HIV-infected Thais. HIV Med 2011; 12: 510-5.
172. Law MG, Friis-Møller N, El-Sadr WM, et al. The use of the Framingham equation to predict myocardial infarctions in HIVinfected patients: comparison with observed events in the D: A: D Study. HIV Med 2006; 7: 218-30.
173. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-52.
174. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviralnaive cohort. HIV Med 2005; 6: 114-21.
175. Miller TI, Borkowsky W, DiMeglio LA, et al. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med 2012; 13: 264-75.
176. Oliviero U, Bonadies G, Apuzzi V et al. Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 2009; 204: 586-9.
177. Torriani F, Komarow L, Parker RA et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy. J Am Coll Cardiol 2008; 52: 569-75.
178. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009; 23: 929-39.
179. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368: 459-65.
180. Arildsen H, Sørensen K, Ingerslev J, Ostergaard L, Laursen A. Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy. HIV Med 2013; 14: 1-9.
181. Baker JV, Neuhaus J, Duprez D, et al. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 2012; 60: 128-34.
182. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res 2012;129(3): 301-8.
183. Fedele F, Bruno N, Mancone M. Cardiovascular risk factors and HIV disease. AIDS Rev 2011; 13: 119-29.
184. Barbaro G, Klatt EC. HIV infection and the cardiovascular system. AIDS Rev 2002; 4: 93-103.
185. Teofili L, Iachininoto MG, Capodimonti S, et al.Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. AIDS 2010; 24: 2443-50.
186. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7: 223-42.
187. Jiang J, Fu W, Wang X, Lin PH, Yao Q, Chen C. HIV gp120 induces endothelial dysfunction in tumour necrosis factor-alphaactivated porcine and human endothelial cells. Cardiovasc Res 2010; 87: 366-74.
188. Paladugu R, Fu W, Conklin BS, et al. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38: 549-55.
189. Duffy P, Wang X, Lin PH, Yao Q, Chen C. HIV Nef protein causes endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J Surg Res 2009; 156: 257-64.
190. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46: 72-7.
191. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
192. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145: 397-406.
193. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24: 1527-35.
194. Lodwick RK, Sabin CA, Porter K, et al. Death rates in HIVpositive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376: 340-5.
195. Gill J, May M, Lewden C, et al. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-96.
196. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS 2010; 24: 1877-86.
197. Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 2007; 8: 547-54.
198. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D: A: D study. AIDS 2010; 24: 1537-48.
199. Islam F, Wu J, Jansson J, Wilson D. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med 2012; 13: 453-68.
200. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-8.
201. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-86.
202. Iloeje UH, Yuan Y, L’Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 37-44.
203. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
204. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIVinfected patients enrolled in the D: A: D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
205. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53: 1120-6.
206. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D: A: D) study. J Infect Dis 2010; 201: 318-30.
207. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228-38.
208. Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23: 2021-7.
209. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIVassociated vascular disease and endothelial dysfunction. World J Surg 2007; 31: 632-43.
210. Wang X, Chai H, Yao Q, Chen C. Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction. J Acquir Immune Defic Syndr 2007; 44: 493-9.
211. Mondal D, Pradhan L, Ali M, Agrawal KC. HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: Exacerbation by inflammatory cytokines and amelioration by antioxidants. Cardiovasc Toxicol 2004; 4: 287-302.
212. Chai H, Yang H, Yan S, et al. Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries. J Acquir Immune Defic Syndr 2005; 40: 12-9.
213. Fu W, Chai H, Yao Q, Chen C. Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression. J Acquir Immune Defic Syndr 2005; 39: 152-8.
214. Wang X, Chai H, Lin PH, Yao Q, Chen C. Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 2009; 174(3): 771-81.
215. Chai H, Yan S, Lin P, Lumsden AB, Yao Q, Chen C. Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries. J Am Coll Surg 2005; 200: 820-30.
216. Chai H, Zhou W, Lin P, Lumsden A, Yao Q, Chen C. Ginsenosides block HIV protease inhibitor ritonavir-induced vascular dysfunction of porcine coronary arteries. Am J Physiol Heart Circ Physiol 2005; 288: H2965-71.
217. Cheng C, Wang X, Weakley SM, et al. The soybean isoflavonoid equol blocks ritonavir-induced endothelial dysfunction in porcine pulmonary arteries and human pulmonary artery endothelial cells. J Nutr 2010; 140: 12-7.
218. Lü JM, Nurko J, Jiang J, et al. Nordihydroguaiaretic acid [NDGA] inhibits ritonavir-induced endothelial dysfunction in porcine pulmonary arteries. Med Sci Monit 2011; 17: BR312-8.
219. Lopez O, Bonnefont-Rousselot D, Edeas M, Emerit J, Bricaire F. Could antioxidant supplementation reduce antiretroviral therapyinduced chronic stable hyperlactatemia? Biomed Pharmacother 2003; 57(3-4): 113-6.
220. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
221. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst [e]inemia in humans. Circulation 1999; 100: 1161-8.
222. He L, Zeng H, Li F, et al. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia. Am J Physiol Endocrinol Metab 2010; 299: E1061-5.
223. Tousoulis D, Bouras G, Antoniades C, et al. Methionine-induced homocysteinemia impairs endothelial function in hypertensives: the role of asymmetrical dimethylarginine and antioxidant vitamins. Am J Hypertens 2011; 24: 936-42.
224. Yan TT, Li Q, Zhang XH, et al. Homocysteine impaired endothelial function through compromised vascular endothelial growth factor/ Akt/endothelial nitric oxide synthase signalling. Clin Exp Pharmacol Physiol 2010; 37: 1071-7.
225. Zhang B, Qiu L, Fu M, Hu S. Interference in mevalonate pathway ameliorates homocysteine-induced endothelium-dysfunction. Eur J Pharmacol 2012; 692: 61-8.
226. Edirimanne VE, Woo CW, Siow YL, Pierce GN, Xie JY, OK. Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to endothelial dysfunction in rats. Can J Physiol Pharmacol 2007; 85: 1236-47.
227. Jiang X, Yang F, Tan H, et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 2005; 25: 2515-21.
228. Eberhardt RT, Forgione MA, Cap A, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst [e]inemia. J Clin Invest 2000; 106: 483-91.
229. Aléssio AC, Santos CX, Debbas V, Oliveira LC, Haddad R, Annichino- Bizzacchi JM. Evaluation of mild hyperhomocysteinemia during the development of atherosclerosis in apolipoprotein Edeficient and normal mice. Exp Mol Pathol 2011; 90: 45-50.
230. Chen C, Conklin BS, Ren Z, Zhong DS. Homocysteine decreases endothelium-dependent vasorelaxation in porcine arteries. J Surg Res 2002; 102: 22-30.
231. Ramaswami G, Chai H, Yao Q, Lin PH, Lumsden AB, Chen C. Curcumin blocks homocysteine-induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2004; 40: 1216-22.
232. Zhou W, Chai H, Courson A, et al. Ginkgolide A attenuates homocysteine- induced endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2006; 44: 853-62.
233. Hedayati N, Annambhotla S, Jiang J, et al. Growth hormonereleasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells. J Vasc Surg 2009; 49: 199-207.
234. Meye C, Schumann J, Wagner A, Gross P. Effects of homocysteine on the levels of caveolin-1 and eNOS in caveolae of human coronary artery endothelial cells. Atherosclerosis 2007; 190: 256-63.
235. Jin L, Caldwell RB, Li-Masters T, Caldwell RW. Homocysteine induces endothelial dysfunction via inhibition of arginine transport. J Physiol Pharmacol 2007; 58: 191-206.
236. Kim CS, Kim YR, Naqvi A, et al. Homocysteine promotes human endothelial cell dysfunction via site-specific epigenetic regulation of p66shc. Cardiovasc Res 2011; 92: 466-75.
237. Rietzschel E, De Buyzere M. High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease? Biomark Med 2012;6(1): 19-34.
238. Teoh H, Quan A, Lovren F, et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 2008; 201: 318-25.
239. Grad E, Golomb M, Mor-Yosef I, et al. Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. Am J Physiol Heart Circ Physiol 2007; 293: H489-95.
240. Singh U, Devaraj S, Vasquez-Vivar J, Jialal I. C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol 2007; 43: 780-91.
241. Valleggi S, Devaraj S, Dasu MR, Jialal I. C-reactive protein adversely alters the protein-protein interaction of the endothelial isoform of nitric oxide synthase. Clin Chem 2010; 56: 1345-8.
242. Mineo C, Gormley AK, Yuhanna IS, et al. FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res 2005; 97: 1124-31.
243. Tanigaki K, Mineo C, Yuhanna IS, Chambliss KL, Quon MJ, Bonvini E, Shaul PW. C-reactive protein inhibits insulin activation of endothelial nitric oxide synthase via the immunoreceptor tyrosinebased inhibition motif of FcgammaRIIB and SHIP-1. Circ Res 2009; 104: 1275-82.
244. Sundgren NC, Zhu W, Yuhanna IS, et al. Coupling of fc_ receptor I to fc_ receptor IIb by SRC kinase mediates C-reactive protein impairment of endothelial function. Circ Res 2011; 109: 1132-40.
245. Chen J, Jin J, Song M, Dong H, Zhao G, Huang L. C-reactive protein down-regulates endothelial nitric oxide synthase expression and promotes apoptosis in endothelial progenitor cells through receptor for advanced glycation end-products. Gene 2012; 496: 128-35.
246. Guan H, Wang P, Hui R, Edin ML, Zeldin DC, Wang DW. Adenoassociated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem 2009; 55: 274-84.
247. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem & Lab Med 1999; 37: 381-8.
248. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acute-phase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009; 14: 187-96.
249. Matsubara T, Ishibashi T, Hori T, et al. Association between coronary endothelial dysfunction and local inflammation of atherosclerotic coronary arteries. Mol Cell Biochem 2003; 249: 67-73.
250. Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol 2008; 295: H2399-408.
251. Witting PK, Song C, Hsu K, et al. The acute-phase protein serum amyloid A induces endothelial dysfunction that is inhibited by high-density lipoprotein. Free Radic Biol Med 2011; 51: 1390-8.
252. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia. TWAR, with chronic coronary heart disease and acute myocardial infarction, Lancet 1988; 2: 983-6.
253. Elkind MS, Tondella ML, Feikin DR, Fields BS, Homma S, Di Tullio MR. Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke. Stroke 2006; 37: 790-5.
254. Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and metaanalysis. Eur Heart J 2002; 23: 371-5.
255. Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study. Circulation 2000; 102: 2335-40.
256. Yavuz MT, Yavuz O, Yazici M, et al. Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis. Scand J Clin Lab Invest 2006; 66: 523-34.
257. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992;82: 158-61.
258. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996; 125: 979-82.
259. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176: 292-5.
260. Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995; 92: 3397-400.
261. Kraml PJ, Roubalová K, Bulvas M, et al. Markers of Chlamydia pneumoniae and human cytomegalovirus infection in patients with chronic peripheral vascular disease and their relation to inflammation, endothelial dysfunction and changes in lipid metabolism. Folia Microbiol 2008; 53: 551-7.
262. Grabczewska Z, Nartowicz E, Kubica J, Rość D. Endothelial function parameters in patients with unstable angina and infection with Helicobacter pylori and Chlamydia pneumoniae. Eur J Intern Med 2006; 17: 339-42.
263. Bouwman JJ, Visseren FL, Bevers LM, van der Vlist WE, Bouter KP, Diepersloot RJ. Azithromycin reduces Chlamydia pneumoniae- induced attenuation of eNOS and cGMP production by endothelial cells. Eur J Clin Invest 2005; 35: 573-82.
264. Liuba P, Pesonen E, Paakkari I, et al. Acute Chlamydia pneumoniae infection causes coronary endothelial dysfunction in pigs. Atherosclerosis 2003; 167: 215-22.
265. Deniset JF, Hedley TE, Dibrov E, Pierce GN. Chlamydophila pneumoniae infection induces alterations in vascular contractile responses. Am J Pathol 2012; 180: 1264-72.
266. Chen C, Chai H, Wang X, Lin PH, Yao Q. Chlamydia heat shock protein 60 decreases expression of endothelial nitric oxide synthase in human and porcine coronary artery endothelial cells. Cardiovasc Res 2009; 83: 768-77.
267. Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein Eknockout mice. Circulation 2000; 102: 1039-44.
268. Liuba P, Pesonen E, Paakkari I, et al. Co-infection with Chlamydia pneumoniae and Helicobacter pylori results in vascular endothelial dysfunction and enhanced VCAM-1 expression in apoE-knockout mice. J Vasc Res 2003; 40: 115-22.
269. Liuba P, Karnani P, Pesonen E, Paakkari I, Persson K, Forslid A. Effects of bradykinin on aortic endothelial function in apoeknockout mice with chronic Chlamydia pneumoniae infection. Circ J 2007; 71: 1480-4.
270. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1-7.
271. Viazzi F, Leoncini G, Ratto E, Pontremoli R. Serum uric acid as a risk factor for cardiovascular and renal disease: an old controversy revived. J Clin Hypertens 2006; 8: 510-8.
272. Krishnan E, Pandya BJ, Chung L, Dabbous O. Hyperuricemia and the risk for subclinical coronary atherosclerosis—data from a prospective observational cohort study. Arthritis Res Ther 2011; 13: R66.
273. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res 2010; 62: 170-80.
274. Galbusera C, Orth P, Fedida D, Spector T. Superoxide radical production by allopurinol and xanthine oxidase. Biochem Pharmacol 2006; 71: 1747-52.
275. Sanders SA, Eisenthal R, Harrison R. NADH oxidase activity of human xanthine oxidoreductase-generation of superoxide anion. Eur J Biochem 1997; 245: 541-8.
276. Johnson RJ, Kang DH, Feig D, Kivilighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazalli M. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-90.
277. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: molecular mechanisms and clinical implications. J Cardiol 2012; 59: 235-42.
278. Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. Am J Nephrol 2011; 33: 298-304.
279. Dopp JM, Philippi NR, Marcus NJ, et al. Xanthine oxidase inhibition attenuates endothelial dysfunction caused by chronic intermittent hypoxia in rats. Respiration 2011; 82: 458-67.
280. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008: 27; 967-78.
281. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effect of the classic antioxidant uric acid in dipocytes: NADPH oxidase mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-96.
282. Yu MA, Sánchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acidinduced endothelial dysfunction. J Hypertens 2010; 28: 1234-42.
283. Hong Q, Qi K, Feng Z, et al. Hyperuricemia induces endothelial dysfunction via mitochondrial Na+/Ca2+ exchanger-mediated mitochondrial calcium overload. Cell Calcium 2012; 51: 402-10.
284. Schwartz IF, Grupper A, Chernichovski T, et al. Hyperuricemia attenuates aortic nitric oxide generation, through inhibition of arginine transport, in rats. J Vasc Res 2011; 48: 252-60.
285. Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. Am J Physiol Cell Physiol 2008; 295: C1183-90.
286. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000; 35: 746-51.
287. Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 2011; 20: 182-7.
288. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105: 2619-24.
289. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114; 2508-16.
290. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 2011; 6: 1887-94.
291. Yelken B, Caliskan Y, Gorgulu N, et al. Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease. Clin Nephrol 2012; 77(4): 275-82.
292. Meléndez-Ramírez G, Pérez-Méndez O, López-Osorio C, Kuri-Alfaro J, Espinola-Zavaleta N. Effect of the treatment with allopurinol on the endothelial function in patients with hyperuricemia. Endocr Res 2012; 37: 1-6.
293. Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1998; 95: 675-80.
294. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999; 340: 143-52.
295. Snieder H, Harshfield GA, Treiber FA. Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension 2003; 41: 1196-201.
296. Grøntved A, Andersen LB, Franks PW, Verhage B, Wareham NJ, Ekelund U, Loos RJ, Brage S. NOS3 variants, physical activity, and blood pressure in the European Youth Heart Study. Am J Hypertens 2011; 24: 444-50.
297. Gatti RR, Santos PS, Sena AA, Marangoni K, Araújo MA, Goulart LR. The interaction of AGT and NOS3 gene polymorphisms with conventional risk factors increases predisposition to hypertension. J Renin Angiotensin Aldosterone Syst 2012 Jul 12. DOI: 10.1177/1470320312452027
298. Li YY. Endothelial nitric oxide synthase G894T gene polymorphism and essential hypertension in the Chinese population: a meta-analysis involving 11,248 subjects. Intern Med 2011; 50: 2099-106.
299. Ong SL, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am 2011; 40: 393-407.
300. Salvi E, Kutalik Z, Glorioso N, et al. Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial no synthase. Hypertension 2012; 59: 248-55.
301. Silva PS, Fontana V, Luizon MR, et al. ENOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril. Eur J Clin Pharmacol 2013; 69: 167-77.
302. Niu W, Qi Y. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS One 2011; 6: e24266.
303. Cilenšek I, Mankoč S, Globočnik Petrovič M, Petrovič D. The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. Mol Biol Rep 2012; 39: 7061-7.
304. Yoshimura M, Yasue H, Nakayama M, et al. Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T-786-->C and missense Glu298Asp variants. J Investig Med 2000; 48: 367-74.
305. Nakayama M, Yasue H, Yoshimura M, et al. T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-70.
306. Salimi S, Naghavi A, Firoozrai M, et al. Association of plasma nitric oxide concentration and endothelial nitric oxide synthase T- 786C gene polymorphism in coronary artery disease. Pathophysiology 2012; 19: 157-62
307. da Costa Escobar Piccoli J, Manfredini V, Hamester FI, et al. Interaction between endothelial nitric oxide synthase gene polymorphisms (-786T>C, 894G>T and intron 4 a/b) and cardiovascular risk factors in acute coronary syndromes. Arch Med Res 2012; 43: 205-11.
308. Zhang K, Bai P, Shi S, et al. The G894T polymorphism on endothelial nitric oxide synthase gene is associated with increased coronary heart disease among Asia population: Evidence from a Meta analysis. Thromb Res 2012; 130: 192-7.
309. Saini V, Bhatnagar MK, Bhattacharjee J. Association of endothelial dysfunction with endothelin, nitric oxide and eNOS Glu298Asp gene polymorphism in coronary artery disease. Dis Markers 2011; 31: 215-22.
310. Ellul J, Markoula S, Marousi S, Galidi A, Kyritsis AP, Papathanasopoulos P, Georgiou I. Association of endothelial nitric oxide synthase polymorphism G894T with functional outcome in acute stroke patients. Neurol Res 2011; 33: 835-40.
311. Hermans MP, Ahn SA, Rousseau MF. ENOS [Glu298Asp] polymorphism, erectile function and ocular pressure in type 2 diabetes. Eur J Clin Invest 2012; 42: 729-37.
312. Angeline T, Krithiga HR, Isabel W, Asirvatham AJ, Poornima A. Endothelial nitric oxide synthase gene polymorphism (G894T) and diabetes mellitus (type II) among South Indians. Oxid Med Cell Longev 2011; 2011: 462607.
313. Joshi MS, Wattanapitayakul S, Schanbacher BL, Bauer JA. Effects of human endothelial gene polymorphisms on cellular responses to hyperglycaemia: role of NOS3 (Glu298Asp) and ACE (I/D) polymorphisms. Diab Vasc Dis Res 2011; 8: 276-83.
314. Shoukry A, Shalaby SM, Abdelazim S, et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of diabetic nephropathy in type 2 diabetes mellitus. Genet Test Mol Biomarkers 2012; 16: 574-9.
315. Alkharfy KM, Al-Daghri NM, Al-Attas OS, et al. Variants of endothelial nitric oxide synthase gene are associated with components of metabolic syndrome in an Arab population. Endocr J 2012; 59: 253-63.
316. Stangl K, Cascorbi I, Laule M, et al. High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics 2000; 10: 133-40.
317. Seelenfreund D, Lobos SR, Quesada A, et al. Association of the intronic polymorphism rs891512 (G24943A) of the endothelial nitric oxide synthase gene with hypertension in Chilean type 2 diabetes patients. Diabetes Res Clin Pract 2012; 96: e47-9.
318. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
319. Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614-20.
320. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-11.
321. Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003; 108: 1049-52.
322. Yan JC, Zhu J, Gao L, et al. The effect of elevated serumsoluble CD40 ligand on the prognostic value in patients with acute coronary syndromes. Clin Chim Acta 2004; 343: 155-9.
323. Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1667-73.
324. Ferro D, Loffredo L, Polimeni L, et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 2007; 27: 2763-8.
325. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001; 104: 2266-8.
326. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation: Part I. Circulation 2003; 108: 1917-23.
327. Chen C, Chai H, Wang X, et al. Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells. Blood 2008; 112: 3205-16.
328. Schneider JJ, Unholzer A, Schaller M, Schafer-Korting M, Korting HC. Human defensins. J Mol Med 2005; 83: 587-95.
329. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J Cell Mol Med 2005; 9: 3-10.
330. Higazi AA, Ganz T, Kariko K, Cines DB. Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells. J Biol Chem 1996; 271: 17650-5.
331. Barnathan ES, Raghunath PN, Tomaszewski JE, Ganz T, Cines DB, Higazi AA-R. Immunohistochemical localization of defensin in human coronary vessels. Am J Pathol 1997; 150: 1009-20.
332. Higazi AA, Lavi E, Bdeir K, et al. Defensin stimulates the binding of lipoprotein [a] to human vascular endothelial and smooth muscle cells. Blood 1997; 89: 4290-8.
333. López-Bermejo A, Chico-Julià B, Castro A, et al. Alpha defensins 1, 2, and 3: potential roles in dyslipidemia and vascular dysfunction in humans. Arterioscler Thromb Vasc Biol 2007; 27: 1166-71.
334. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Neutrophil antimicrobial peptide alpha-defensin causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2006; 43: 357-63.
335. Bechara C, Wang X, Chai H, Lin PH, Yao Q, Chen C. Growthrelated oncogene-alpha induces endothelial dysfunction through oxidative stress and downregulation of eNOS in porcine coronary arteries. Am J Physiol Heart Circ Physiol 2007; 293: H3088-95.